Trial Profile
A multicenter, randomized, double-blind, double dummy, parallel group, dose ranging study of subcutaneous SR123781A with an enoxaparin calibrator arm in the prevention of venous thromboembolism in patients undergoing elective total hip replacement surgery.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 21 Nov 2016
Price :
$35
*
At a glance
- Drugs SR 123781 (Primary) ; Enoxaparin sodium
- Indications Thromboembolism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms DRIVE
- Sponsors Sanofi
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2006-000152-41).
- 09 Dec 2008 Additional trial identifier EudraCT2006-000152-41 reported by ClinicalTrials.gov.
- 15 Apr 2008 Primary endpoint results have been published